23 results
10-Q
EX-10.1
9ff tj5dk
10 May 21
Quarterly report
8:58am
10-Q
u2ncnlat6u2qdexgl9
10 May 21
Quarterly report
8:58am
424B5
th293tf52v 03ot
21 Apr 21
Prospectus supplement for primary offering
4:45pm
424B5
hz5msykcb19nhdoz
19 Apr 21
Prospectus supplement for primary offering
4:57pm
S-3ASR
38f0zlbdrzh92ftz
19 Apr 21
Automatic shelf registration
4:11pm
10-K
m2ucqp
1 Mar 21
Annual report
12:00am
424B5
qpoxj mx1wsmzjgy
23 Sep 20
Prospectus supplement for primary offering
8:06am
424B5
5at3aclbx4ny7ldqn
16 Sep 20
Prospectus supplement for primary offering
7:24am
6-K
EX-99.1
rsmnahjvwyptcyo1d2
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
ayr2hyngst0sp
8 Apr 20
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
6:03am